Munzarová M, Kovarík J, Hlávková J
Czech Med. 1986;9(1):44-50.
551 clinical records of breast cancer patients were retrospectively analysed. Several parameters have been examined: age at presentation, distribution of stages at the time of diagnosis, incidence of any progression and "progression- free" interval after primary treatment, incidence of distant dissemination and distant meta- free interval, cancer mortality, time of survival from presentation and time of survival from detection of distant metastases (stage at presentation being taken into account in all evaluations). The results within various ABO blood groups were mutually compared. There were no substantial differences in these parameters within different blood groups. Immunological point of view, dealing with possible loss or modifications of ABH (O) isoantigens on tumour cells and the immune response to these alien antigens, is discussed.
对551例乳腺癌患者的临床记录进行了回顾性分析。检查了几个参数：就诊时的年龄、诊断时的分期分布、任何进展的发生率以及初次治疗后的“无进展”间隔、远处转移的发生率和无远处转移间隔、癌症死亡率、从就诊开始的生存时间以及从检测到远处转移开始的生存时间（在所有评估中均考虑就诊时的分期）。对不同ABO血型组的结果进行了相互比较。不同血型组在这些参数上没有实质性差异。从免疫学角度讨论了肿瘤细胞上ABH（O）同种抗原可能的丢失或改变以及对这些外来抗原的免疫反应。
